Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity

v3.19.1
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning Balance at Dec. 31, 2017 $ 21,391 $ 60 $ 165,825 $ (340) $ (144,154)
Balance (in shares) at Dec. 31, 2017   59,943      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (7,901)       (7,901)
Equipois supply and sales earn-outs 28   28    
Equipois supply and sales earn-outs (in shares)   18      
Equity incentive plan (in shares)   52      
Matching contribution to 401(k) plan 508   508    
Matching contribution to 401(k) plan (in shares)   221      
In lieu of cash compensation 190   190    
In lieu of cash compensation (in shares)   121      
Stock-based compensation expense 830   830    
Foreign currency translation adjustments (207)     (207)  
Ending Balance at Mar. 31, 2018 14,839 $ 60 167,381 (547) (152,055)
Balance (in shares) at Mar. 31, 2018   60,355      
Beginning Balance at Dec. 31, 2018 2,728 $ 63 173,903 (92) (171,146)
Balance (in shares) at Dec. 31, 2018   62,963      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (6,551)       (6,551)
Equity financing, net 7,305 $ 5 7,300    
Equity financing, net (in shares)   4,362      
Equipois supply and sales earn-outs 22   22    
Equipois supply and sales earn-outs (in shares)   18      
Equity incentive plan 55   55    
Equity incentive plan (in shares)   45      
Matching contribution to 401(k) plan 191   191    
Matching contribution to 401(k) plan (in shares)   141      
Stock-based compensation expense 636   636    
Foreign currency translation adjustments 148     148  
Ending Balance at Mar. 31, 2019 $ 4,534 $ 68 $ 182,107 $ 56 $ (177,697)
Balance (in shares) at Mar. 31, 2019   67,529